How skincare is regulated in the US: cosmetic vs drug, and where GHK-Cu fits
Share
Updated November 2026. Every rule below links to the FDA page, statute or Federal Register notice it comes from, with the date we checked it.
The short answer: no. GHK-Cu is not FDA approved, in any form, and a copper peptide serum isn't supposed to be. In the US, skin-care products sold to change how skin looks are cosmetics, and the FDA doesn't approve cosmetics or their ingredients before they go on sale (color additives are the exception). It does regulate them, more tightly since a 2022 law called MoCRA. Injectable and compounded GHK-Cu are a different category altogether: they would be drugs, no GHK-Cu drug has been approved, and as of November 2026 the FDA is still deciding whether non-injectable GHK-Cu belongs on the list of bulk substances pharmacies may compound from, and says it will consult its advisory committee first.
That is a lot of "it depends", so this page takes it apart in order: how US law decides whether a product is a cosmetic or a drug, what MoCRA added, where GHK-Cu sits in each category, what a serum is and isn't allowed to say, and what to check on the label before you buy. We make a copper peptide serum, so we've stuck to primary sources and said where the rules are still moving.
Shopping from Australia? The rules there are different. See our guide to cosmetic vs therapeutic rules in Australia.
Cosmetic or drug? US law decides by intended use
The Federal Food, Drug, and Cosmetic Act (the FD&C Act) defines both categories by what a product is intended to do, not by what is in it.
- A cosmetic is something applied to the body for cleansing, beautifying, promoting attractiveness or altering the appearance. Soap, oddly, is carved out of the definition (21 U.S.C. 321(i)).
- A drug is something intended to diagnose, cure, mitigate, treat or prevent disease, or intended to affect the structure or any function of the body (21 U.S.C. 321(g)(1)).
That second clause, "structure or any function", is the one that catches skin care. A serum that promises to make skin look smoother is making a cosmetic claim. A serum that promises to rebuild, regenerate or repair skin is describing a change in how the body works, which is the kind of wording the FDA treats as drug territory.
The FDA works out intended use from three things (FDA, "Is It a Cosmetic, a Drug, or Both?"):
- Claims on the label, in ads, on the website and on social media. The FDA's own examples of claims that turn a cosmetic into a drug include restoring hair growth, reducing cellulite and regenerating cells.
- Consumer perception: why people buy it and what they expect it to do.
- Ingredients with a well-known therapeutic use, such as fluoride in toothpaste.
So the same bottle can become an unapproved drug through how it's marketed, even if it's sold like a cosmetic.
Products that are both
Some products are cosmetics and drugs, and have to meet the rules for both. The FDA's examples include a moisturizer or foundation with SPF, an anti-dandruff shampoo, an antiperspirant-deodorant and fluoride toothpaste that also freshens breath. You can usually spot these by the Drug Facts panel on the box, with the drug's active ingredient listed first. A plain peptide serum making appearance claims has no Drug Facts panel, because it isn't a drug.
What "FDA approved" does and doesn't mean for skin care
"Approved" and "regulated" get used as if they mean the same thing. In US skin care they don't.
- Cosmetics: no pre-market approval, for the product or for most ingredients. The exception is color additives, which do need FDA approval. Instead, the company that makes or sells a cosmetic is legally responsible for making sure it is safe, and it can't be adulterated or misbranded (FDA, "FDA Authority Over Cosmetics").
- Drugs: generally need either an approved New Drug Application or to meet an over-the-counter monograph for their category, such as sunscreen (FDA).
- Compounded drugs, made by a pharmacy for an individual patient, are also not FDA approved. The FDA doesn't verify their safety, effectiveness or quality before they're marketed (FDA, "Compounding and the FDA").
So "FDA approved" on a serum is a warning sign rather than a selling point. Either the brand is misusing the phrase, or it's describing a drug. "FDA registered" means something narrower again, which is where MoCRA comes in.
MoCRA: what changed for US skin-care brands in 2022
The Modernization of Cosmetics Regulation Act of 2022 was signed on December 29, 2022, as part of the Consolidated Appropriations Act, 2023 (Pub. L. 117-328) (FDA registration and listing guidance). The FDA describes it as the most significant expansion of its authority over cosmetics since the FD&C Act passed in 1938 (FDA, "Cosmetics & U.S. Law"). It still doesn't introduce pre-market approval. What it does add:
| Requirement | What it means |
|---|---|
| Facility registration | Facilities that manufacture or process cosmetics for the US register with the FDA and renew every two years. Initial registrations were due by December 29, 2023, and the FDA said it wouldn't enforce until July 1, 2024. |
| Product listing | The "responsible person" lists every cosmetic product it sells in the US, with its ingredients, and updates the listing each year. |
| Responsible person | The manufacturer, packer or distributor whose name appears on the label. They carry the listing, reporting and safety duties. |
| Serious adverse event reporting | Serious reactions reported to the brand must be sent to the FDA within 15 business days, with a copy of the label. "Serious" covers things like hospitalization, significant disfigurement, infection, or anything needing medical intervention to prevent those outcomes. |
| Safety substantiation | The responsible person must have, and keep records of, adequate evidence that the product is safe. MoCRA doesn't require specific tests, and doesn't require animal testing. |
| A contact on the label | Every cosmetic label must carry a US address, a US phone number or electronic contact information (a website is allowed) where adverse events can be reported. |
| Records and recalls | The FDA can access certain safety records and can order a mandatory recall when a product poses a reasonable probability of serious harm and the company won't recall it voluntarily. |
| Still to come | FDA must still establish cosmetic good manufacturing practice requirements (draft guidance only so far) and fragrance allergen labeling requirements. A proposed talc asbestos-testing rule was published in December 2024 and withdrawn in November 2025. |
Sources: FDA MoCRA overview (current as of October 29, 2026); FDA registration and listing page; FDA registration and listing guidance.
Two details are worth knowing as a shopper. First, small businesses (average US cosmetic sales under $1 million a year over the previous three years, adjusted for inflation) are exempt from registration and listing, though not if they make products that regularly contact the mucous membrane of the eye, are injected, are for internal use or are intended to alter appearance for more than 24 hours. So a missing registration isn't automatically a red flag for a tiny brand. Small businesses are still subject to the adverse-event, safety-substantiation and labeling rules. Second, registration and listing are filings. They tell the FDA who makes what, and where. They are not a review of the product, and a brand calling itself "FDA registered" is not telling you the FDA has checked its formula.
Where GHK-Cu fits
GHK-Cu is a small peptide (glycine, histidine and lysine) bound to copper. On a US ingredient list it usually appears under its standard cosmetic ingredient name, Copper Tripeptide-1, which industry databases list as a skin-conditioning ingredient (COSMILE Europe). For the chemistry, see what GHK-Cu is and how it works.
Which rules apply depends on the product it's in and how it's sold:
| Form | Category | FDA approved? | Status, November 2026 |
|---|---|---|---|
| Topical serum or cream with appearance claims | Cosmetic | No, and not required | Can be sold if it's safe, properly labeled and makes only cosmetic claims. MoCRA duties apply. |
| Topical product claiming to heal, treat or regrow | Drug | No | Would be an unapproved drug. No approved drug containing GHK-Cu turns up in the FDA's Drugs@FDA database. |
| Compounded GHK-Cu, non-injectable (prescription) | Compounded drug | No (compounded drugs never are) | Under evaluation in the FDA's 503A "Category 1". The FDA says it will hold an advisory committee meeting on it before the end of February 2027 (date not yet announced). |
| Compounded GHK-Cu for injection | Compounded drug | No | Nomination withdrawn (it had been in Category 2). The FDA has published safety concerns about compounded injectable GHK-Cu. |
| "Research use only" vials sold online | None of the above | No | Not sold as a cosmetic, not dispensed under a prescription, not an approved drug. |
The topical serum: a cosmetic
A copper peptide serum sold for the look and feel of skin is a cosmetic like any other. It needs no FDA approval, and it can't claim one. What decides whether it stays a cosmetic is the language around it. "Skin looks firmer and smoother" is a cosmetic claim. "Stimulates collagen to repair aging skin" describes a change to the body's structure, and that's the sort of wording that can tip a product into the drug category. More on wording below.
Compounded GHK-Cu and the 503A list
Under section 503A, a pharmacist compounds a drug for an identified individual patient on a valid prescription (the law also allows limited quantities in advance for established prescribers). Each bulk ingredient must comply with a US Pharmacopeia monograph where one exists. If none exists, it must be a component of an FDA-approved drug or appear on a list the FDA develops by regulation, known as the 503A bulks list (21 U.S.C. 353a). GHK-Cu is not on that list yet, and we found no approved drug containing it.
While the FDA works through nominations for the list, it sorts them into three categories (FDA, 503A bulk drug substances):
- Category 1, under evaluation. The FDA doesn't intend to take action against pharmacies compounding with these substances while it decides, provided they follow the conditions in its guidance.
- Category 2, significant safety concerns. No such forbearance.
- Category 3, nominated without enough supporting information. No forbearance either.
Here is GHK-Cu's 2026, from the FDA's own nominated-substances list, last updated May 14, 2026 (FDA, PDF):
- April 22, 2026: GHK-Cu for non-injectable routes was removed from Category 1, because the nominations had been withdrawn.
- May 5, 2026: one nominator clarified that it had only meant to withdraw the injectable nomination and wanted to keep the non-injectable one.
- Result: GHK-Cu (except for injectable routes) goes back into Category 1, and the FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about adding GHK-Cu to the bulks list.
The FDA's advisory committee page lists GHK-Cu alongside cathelicidin (LL-37), dihexa acetate, melanotan II and pegylated mechano growth factor for that meeting, date still to be set (FDA PCAC). GHK-Cu was not among the seven peptides on the agenda for the committee's July 23–24, 2026 meeting (Federal Register, 91 FR 20465).
Keep the stakes in proportion. Committee votes are advice, not decisions. Even if GHK-Cu is eventually added to the bulks list, that would let licensed pharmacies compound it for patients with a prescription. It would not make GHK-Cu an FDA-approved drug, and it wouldn't change anything about cosmetic serums.
Injections and "research use only" peptides
Injectable GHK-Cu was nominated for the 503A list and then withdrawn. On its page of substances that may raise safety concerns, the FDA notes that compounded injectable GHK-Cu could carry a risk of immune reactions because the peptide can clump together (aggregate) and pick up peptide-related impurities, and that human data are limited (FDA).
The vials sold online as "research use only" or "not for human use" sit outside every category on this page. They aren't cosmetics, they aren't dispensed by a pharmacy for a named patient, and they aren't approved drugs. The label signals the seller is not offering them as a cosmetic or a prescribed medicine, and no FDA review of their safety or quality applies. If you're thinking about injectable peptides, talk to a doctor. A serum and an injection aren't two strengths of the same thing.
What a peptide serum can and can't claim
The FDA polices whether a claim makes a product a drug. The Federal Trade Commission polices whether advertising is truthful, and its guidance says health-related claims need competent and reliable scientific evidence, and that implied claims count as much as stated ones (FTC Health Products Compliance Guidance). Here is how that tends to play out in practice:
| Cosmetic wording (appearance) | Drug-style wording (structure, function, disease) |
|---|---|
| "Skin looks smoother and more even" | "Repairs damaged skin" |
| "Supports the look of firmness" | "Stimulates collagen production" |
| "Reduces the appearance of fine lines" | "Reverses aging" or "regenerates cells" |
| "Skin feels soft and comfortable" | "Heals" or "treats" acne, eczema, rosacea or scarring |
| "Hair looks fuller" (styling) | "Regrows hair" |
| "A gentle night step" | "Works like injections" or "as effective as tretinoin" |
This table is a guide to the kind of wording, not a legal test. The FDA looks at all the claims, how the product is sold and what buyers expect.
The right-hand column is wording we won't use. When you see it on a serum, the brand is either selling an unapproved drug or overselling a cosmetic, and neither is a good sign. Lab and animal studies on GHK-Cu are interesting, but they don't let a cosmetic make drug claims. For a fair read of what the human evidence shows, see GHK-Cu vs retinol: what the evidence actually shows.
What to check on a US skin-care label
The FDA's labeling rules, plus MoCRA, give you a practical checklist (FDA, Summary of Cosmetics Labeling Requirements):
- What it is. The front panel should name the product and say what it's for (21 CFR 701.10).
- How much is in it. A net contents statement on the front, in fluid ounces for liquids. Metric can be added alongside.
- Who is responsible. A name and place of business, with "Distributed by" or "Manufactured for" if that company didn't make it (21 CFR 701.12).
- A way to report a reaction. A US address, a US phone number or electronic contact information (a website is allowed) for adverse-event reports. That's a MoCRA requirement.
- A full ingredient list. Ingredients over 1% appear in descending order of amount. Those at 1% or less can appear in any order (21 CFR 701.3). For a copper peptide serum, look for Copper Tripeptide-1. If it's listed near the very end, that tells you little on its own, since the 1% rule lets brands put low-level ingredients anywhere. Ask what the actual concentration is.
- No Drug Facts box unless it really is a drug-cosmetic (an SPF, say). If a serum has one, check what the active ingredient is.
- Cosmetic claims only. Use the table above. "FDA approved" on a serum is a red flag.
- Evidence of strength. The law doesn't require a brand to tell you how much GHK-Cu is in the bottle. A good brand will anyway, and will back it with a test on the finished product. Here's how to read a certificate of analysis (COA).
If you do have a reaction, stop using the product, see a healthcare provider if you need to, and tell the brand. You can also report it to the FDA directly through MedWatch online, or by calling 1-888-SAFEFOOD (option 4) (FDA). For what's known about tolerance, sensitivity and pregnancy, see is GHK-Cu safe?
How aijaé approaches this
We position the aijaé Peptide Serum as a cosmetic, and we write about it that way. It's a night-time copper peptide serum built around GHK-Cu, designed in Australia and made in Singapore.
- Strength we can show: 1% GHK-Cu, assay-verified. Every batch is tested by HPLC in the finished product, and the certificate of analysis goes with the batch number printed on the bottle.
- Cosmetic claims only. We talk about how skin looks and feels, never about treating, repairing or regrowing anything, and we don't compare it to injections or prescription retinoids.
- Why it's blue: the color comes from the copper. It's fragrance-free and colorant-free.
- US details: one 30 mL bottle lasts 60 nights. It's $129 once, $97 a bottle on the 60-day subscription, or $237 for three bottles every 180 days ($79 a bottle). US orders ship free from within the US.
If a serum is all you're after, you don't need a prescription, a pharmacy or a syringe. If you're weighing injectable peptides, that's a conversation for a doctor, not a skin-care brand.
What to watch next
- The FDA's compounding advisory committee meeting on GHK-Cu, due before the end of February 2027. Whatever it recommends, the FDA still has to decide, and adding a substance to the 503A list takes formal rulemaking. None of that would affect cosmetic serums.
- MoCRA rules still to come, including cosmetic good manufacturing practice and fragrance allergen labeling.
We'll update this page when either moves.
Frequently asked questions
Is GHK-Cu FDA approved?
No. GHK-Cu isn't FDA approved for any use, and no approved drug containing it turns up in the FDA's Drugs@FDA database. Topical serums don't need approval because they're cosmetics. The FDA doesn't pre-approve cosmetics or their ingredients, apart from color additives.
Is it legal to buy a GHK-Cu serum in the US?
Generally, yes. A copper peptide serum sold as a cosmetic can be sold in the US if it is safe, properly labeled, free of prohibited ingredients and makes appearance claims rather than drug claims. Since MoCRA, most brands must also register facilities, list products and report serious adverse events to the FDA. Small businesses are exempt from registration and listing but not from the other duties.
Are copper peptide injections FDA approved?
No. There's no approved injectable GHK-Cu drug. The nomination to allow compounding of injectable GHK-Cu was withdrawn, and the FDA has flagged possible immune reactions from aggregation and impurities, with limited human data. Talk to a doctor before considering any injectable peptide.
Is GHK-Cu getting FDA approved?
Not in the sense most people mean. What's under review is whether pharmacies can compound non-injectable GHK-Cu under prescription. The FDA plans to consult its advisory committee before the end of February 2027. Even a yes would not make GHK-Cu an FDA-approved drug.
What does "FDA registered" mean on skin care?
Under MoCRA, cosmetic facilities register with the FDA and brands list their products. Those are filings, not reviews. "FDA registered" doesn't mean the FDA has tested or endorsed the formula, and "FDA approved" on a cosmetic is a red flag.
What can a peptide serum claim?
Appearance claims, such as "skin looks smoother" or "supports the look of firmness". Claims to treat disease or change the body's structure or function, such as repairing skin, stimulating collagen production or regrowing hair, make a product a drug in the eyes of the law. This is a guide to the kind of wording, not a legal test. The FDA looks at all the claims, how the product is sold and what buyers expect.
How do I report a reaction to a cosmetic?
Stop using it, see a healthcare provider if you need to, and tell the brand. Under MoCRA, the label must show a US address, a US phone number or electronic contact information (a website is allowed) for reports. You can also report to the FDA through MedWatch or by calling 1-888-SAFEFOOD (option 4).
Sources
All opened and checked November 20, 2026. Dates in brackets are the "content current as of" date on each FDA page.
- 21 U.S.C. 321(g)(1) and 321(i): definitions of drug and cosmetic. Cornell LII
- 21 U.S.C. 353a: pharmacy compounding (section 503A). Cornell LII
- FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) [09/11/2024]. fda.gov
- FDA. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated [11/18/2025]. fda.gov
- FDA. Modernization of Cosmetics Regulation Act of 2022 (MoCRA) [10/29/2026]. fda.gov
- FDA. Cosmetics & U.S. Law [08/17/2026]. fda.gov
- FDA. Guidance for Industry: Registration and Listing of Cosmetic Product Facilities and Products. fda.gov (PDF)
- FDA. Registration and Listing of Cosmetic Product Facilities and Products [09/09/2026]. fda.gov
- FDA. Summary of Cosmetics Labeling Requirements [11/18/2025]. fda.gov
- FDA. How to Report a Cosmetic Product Related Complaint [10/05/2026]. fda.gov
- FDA. Compounding and the FDA: Questions and Answers [09/16/2025]. fda.gov
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act [05/14/2026]. fda.gov
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026). fda.gov (PDF)
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks [04/22/2026]. fda.gov
- FDA. Meeting of the Pharmacy Compounding Advisory Committee (GHK-Cu and four other substances; date to be announced) [04/15/2026]. fda.gov
- Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting. 91 FR 20465, April 16, 2026 (doc. 2026-07361). federalregister.gov
- FDA. Drugs@FDA database (searched via openFDA for GHK-Cu / prezatide copper, no approved products found, November 20, 2026). accessdata.fda.gov
- Federal Trade Commission. Health Products Compliance Guidance. ftc.gov
- COSMILE Europe. Copper Tripeptide-1 (ingredient entry). cosmileeurope.eu
This article is general information about US cosmetic regulation and skin care. It isn't legal or medical advice. If you have a skin condition, are pregnant or are considering any injectable or prescription product, speak to your doctor or pharmacist.